ZTS
38
4
PYPL
49
4
PRU
39
3
ED
39
8
ZION
49
9
EBAY
42
2
NI
63
5
CAG
34
3
LRCX
56
4
M
40
3
ESS
44
5
CLX
65
2
DIS
70
2
FIS
43
5
RCL
74
5
EQR
33
6
IPG
43
3
KSS
36
2
LNC
28
3
EOG
28
2
ZTS
38
4
PYPL
49
4
PRU
39
3
ED
39
8
ZION
49
9
EBAY
42
2
NI
63
5
CAG
34
3
LRCX
56
4
M
40
3
ESS
44
5
CLX
65
2
DIS
70
2
FIS
43
5
RCL
74
5
EQR
33
6
IPG
43
3
KSS
36
2
LNC
28
3
EOG
28
2
Financhill
Back

LanzaTech Global 10K Form

Sell
40

LNZA
LanzaTech Global

Last Price:
$1.03
Seasonality Move:
-36.61%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LNZA News And Ratings

See the #1 stock for the next 7 days that we like better than LNZA

LNZA Financial Statistics

Sales & Book Value

Annual Sales: $62.6M
Cash Flow: $-26.7M
Price / Cash Flow: 0
Annual Sales: $0.07
Price / Book: 14.83

Profitability

EPS (TTM): -0.65000
Net Income (TTM): $-129.4M
Gross Margin: $17.7M
Return on Equity: -155.58%
Return on Assets: -57.23%

LanzaTech Global Earnings Forecast

Key LanzaTech Global Financial Ratios

  • The Gross Profit Margin over the past 4 years for LNZA is 28.18%.
  • The Selling, General & Administrative Expenses for LNZA have been equal to 80.53% of Gross Profit Margin.
  • The Research & Development expenses have been 108.80% of Revenue.
  • The Interest Expense is -0.01% of Operating Income.
  • The Net Earning history of LNZA is -214.11% of Total Revenues.
  • Per Share Earnings over the last 4 years have been positive in 0 years.

LanzaTech Global Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial Services & Supplies
Sector: Industrials
Current Symbol: LNZA
Website: lanzatech.com

Debt

Debt-to-Equity Ratio: 4.53
Current Ratio: 2.91
Quick Ratio: 2.57

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LNZA Technical Analysis vs Fundamental Analysis

Sell
40
LanzaTech Global (LNZA) is a Sell

Is LanzaTech Global a Buy or a Sell?

  • LanzaTech Global stock is rated a Sell
    The current LanzaTech Global [LNZA] share price is $1.02. The Score for LNZA is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.